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Abstract Copper (Cu) is an essential microelement
found in all living organisms with the unique ability to
adopt two different redox states—in the oxidized
(Cu2?) and reduced (Cu?). It is required for survival
and serves as an important catalytic cofactor in redox
chemistry for proteins that carry out fundamental
biological functions, important in growth and devel-
opment. The deficit of copper can result in impaired
energy production, abnormal glucose and cholesterol
metabolism, increased oxidative damage, increased
tissue iron (Fe) accrual, altered structure and function
of circulating blood and immune cells, abnormal
neuropeptides synthesis and processing, aberrant car-
diac electrophysiology, impaired myocardial contrac-
tility, and persistent effects on the neurobehavioral and
the immune system. Increased copper level has been
found in several disorders like e.g.: Wilson’s disease or
Menke’s disease. New findings with the great potential
for impact in medicine include the use of copper-
lowering therapy for antiangiogenesis, antifibrotic and
anti-inflammatory purposes. The role of copper in
formation of amyloid plaques in Alzheimer’s disease,
and successful treatment of this disorder in rodent
model by copper chelating are also of interest. In this
work we will try to describe essential aspects of copper
in chosen diseases. We will represent the evidence
available on adverse effect derived from copper
deficiency and copper excess. We will try to review
also the copper biomarkers (chosen enzymes) that help
reflect the level of copper in the body.
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Copper complexes
Distribution, storage, uptake
Copper is absorbed from diet, mainly in duodenum,
although it is thought that some absorption takes place in
the stomach and in the distal part of the small intestine.
Copper uptake into enterocyte is managed mainly by
human copper transport protein 1 (hCTR1). The
processes is mediated by action of reductases in the
apical membrane, which reduce dietary Cu(II) to
Cu(I)—the acceptable state of copper for this receptor.
Recent studies show that transport of Cu(I) ions can be
carried out using the divalent metal transporter 1—it is
an iron transport protein located on the membrane of
enterocytes. Following absorption by the gut, copper is
secreted into the circulation and bound as Cu(II) to
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albumin, transcuprein and low molecular weight cop-
per-histidine complexes. Upon gaining the liver, copper
is rapidly taken up by hepatocytes also via hCTR1.
Inside the cytoplasm of cells, copper is either chelated
by metallothionein (MT) for storage or it binds to a
copper chaperone for delivery to specific proteins or it
binds to reduced glutathione. Three copper chaperones
have been identified: CCS (copper chaperone for
superoxide dismutase 1), COX17 (chaperone for cyto-
chrome c oxygenase) and ATOX1 (chaperone for
ATPases—ATP7A and B). ATP7A delivers copper to
tyrosinase and ATP7B to lysyl oxidase and ceruloplas-
min (Cp) (Turecky et al. 1984; de Romana et al. 2011).
Multicompartment studies with isotopic traces and
kinetic modeling confirm that there is a relatively little
copper storage, about 80–100 mg, mostly in the liver,
followed by brain, kidney and heart (Jacobs and Wood
2003; Thiele 2003; Pen˜a et al. 2000). Copper is excreted
into gastrointestinal tract, either via the bile or as non-
absorbed copper. Only 10–15 % of copper in bile is
reabsorbed. Excess of copper is eliminated in feces, both
as absorbed and unabsorbed metal ions and from biliary
excretion, averaging 0.5–1.3 mg per day, and with small
amounts in urine, saliva and perspiration. The average
intake of copper by human adults varies from 0.6 to
1.6 mg per day and the main sources are seeds, grains,
nuts and beans, shellfish and liver (Tapiero et al. 2003;
Thiele 2003). Several dietary factors have been pro-
posed as possible modifiers of copper absorption in
humans. For example recent studies have shown that
patients who have used the denture cream enriched with
zinc too often, suffered from progressive myelopoly-
neuropathy which was due to copper deficiency (Hedera
et al. 2009; Nations et al. 2008; de Romana et al. 2011).
Certain prebiotic, naturally present or added to food,
such as short-chain fructooligosaccharides, pectin and
inulin, have a positive effect on copper absorption.
Ascorbic acid and its salts used in food industry (E300—
E3004), phytate (found in cereals—especially bran,
seeds of legumes and nut), EDTA-Na/Fe and polyphe-
nols do not seem to affect its absorption.
Diseases related with copper deficiency or excess
Menke disease and Wilson disease
Essentiality and toxicity of copper are well character-
ized by two rare genetic conditions: Menkes disease
(MD) and Wilson disease (WD). Wilson’s disease
(autosomal recessive) and Menke’s disease (X-linked)
represent the most well recognized and understood
disorders of copper homeostasis (Shim and Harris
2003). They are caused by recessive defects in genes,
ATP7B and ATP7A, which are differentially
expressed in tissues (ATP7B is expressed in the
TGN membrane of hepatocyte, ATP7A-on the TGN
membrane of the placenta, gut and brain respectively).
Both the proteins made by ATP7A and by ATP7B are
membrane-bound copper-transporting ATPases (Shim
and Harris 2003).
Menke disease is an X-linked inherited disorder,
and it is caused by a mutation in the ATP7A gene. This
gene encodes a copper transporting ATPase. The
ATP7A gene product functions as an intracellular
pump to transport copper into the trans-Golgi network
for incorporation into copper requiring enzymes
including dopamine b–hydroxylase and also mediates
copper exodus from cells. Mutations in this gene
appear as disorders of copper deficiency and lead to
hypothermia neuronal degeneration, mental retarda-
tion abnormalities in hair (scalp hair called kinky or
steel wool), bone fractures, and aortic aneurysms
(Uriu-Adams and Keen 2005). A failure of function of
ATP7A in the intestine leads to a failure of copper
efflux from intestine, accumulation of excess copper in
the intestine, a failure of copper absorption into the
blood, and generalized copper deficiency. The failure
of function of ATP7A in the blood brain barrier leads
to a failure of copper efflux from cells of this barrier,
accumulation of copper in these cells, and a failure of
copper uptake in the brain, even if circulating copper
levels are normalized by parenteral copper therapy
(Brewer 2003a, b).
Wilson’s disease (WD) is an autosomal recessive
genetic disorder, and is caused by disabling mutations in
both copies of the ATP7B gene. This gene is responsible
for copper’s transfer into the secretory pathway for both
binding into Cp and excretion into the bile (Brewer
2000). Clinical manifestations are liver disease and
neurological damage. The cornea of the eye is also
affected, resulting in the hallmark brown discoloration
of the cornea, which is very specific for neurological
WD, the Kayser Fleischer ring’’ (Tapiero et al. 2003).
Despite high hepatic copper levels, Cp and copper
concentrations in blood are low, while urinary copper
excretion is increased. When Wilson’s disease is
recognized in time, it can be treated in several ways,
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including the use of chelating agents (such as EDTA-K2/
Ca, 2,3-dimercaptopropan-1-ol), high levels of zinc
supplements (40–50 mg three times per day) and low Cu
diet (Uriu-Adams and Keen 2005). The therapy of
Wilson’s disease is mostly based on Zn addition to the
food, penicillamine addition and tetrathiomolybdate
(TM) or trientine (triethylene tetramine dihydrochlo-
ride). The first line therapy for asymptomatic patients
and for those with mild hepatic disease is zinc in form of
sulphate or acetate. Main mechanism in which zinc is
efficacious for Wilson disease is that zinc competes with
copper for similar binding sites—its mechanism of
action depends on interfering with uptake of copper
from the gastrointestinal tract (Abuduxikuer and Wang
2014; Wang et al. 2013; Wiernicka et al. 2013; Ugarte
et al. 2013). Zinc probably may also act by induction of
intestinal cell metallothionein. Metallothionein T, once
induced, has a high affinity for binding copper and
prevents the serosal transfer of copper into the blood.
The intestinal cells turnover rapidly and take the
complexed copper into the stool for final excretion.
Zinc not only blocks food copper but also the copper that
is endogenously excreted via salivary, gastric, and other
gastrointestinal juices. Thus, zinc is effective in pro-
ducing a chronic negative copper balance (Litwin et al.
2013; Prasad 2013; Roney and Colman 2004; Ugarte
et al. 2013). Penicillamine mechanism of action involves
reductive chelation of copper in the body, and enhanced
excretion of copper in the urine (Butler et al. 2001;
Brewer 2000). Penicillamine binds copper with sulfhy-
dryl groups and this complex is subsequently removed
from the organism via the urine. Trientine has a
polyamine-like structure that allows copper binding by
forming a stable complex with four constituent nitro-
gen’s in a planar ring. Like penicillamine, trientine
promotes copper excretion in the urine (Gromadzka
et al. 2014). TM mechanism of action involves the
formation of a tripartite complex with protein and
copper, and in this way prevents the absorption of copper
from gastrointestinal tract. TM taken with meals asso-
ciates with copper present in food, thereby preventing
copper reabsorption (Yoshii et al. 2001). If TM is given
between meals, it is also absorbed into the bloodstream,
where it binds either free copper ions or copper loosely
bound with serum albumin (Brewer et al. 2000). Such
complex is no longer available for cellular uptake,
possesses no biological activity and is cleared in bile and
urine (Kalita et al. 2014; Nasulewicz et al. 2004).
Infantile and childhood copper toxicosis
syndromes
Syndrome called idiopathic copper toxicosis (ICT)
occurring in infants and young children has been seen
in many parts of the world, and is usually associated
with high levels of hepatic copper, caused by high
concentrations of copper in drinking water or food
(Brewer 2003a, b). In west Austria, Germany and in
Italy in years 1900–1980 about 138 infants died
because of this disease. Similarly, in India the infants
who were fed milk stored in brass or copper containers
developed a disease known as Indian Childhood
Cirrhosis (ICC), in which liver has increased levels
of copper. ICC is characterized pathologically by a
micro-micronodular cirrhosis, accumulation of Mal-
lory’s hyaline in necrotic hepatocytes, distinctive
orcein positive granules and striking lack of regener-
ative nodule, with no chronic biliary disease (Baker
et al. 1995). All these syndromes (ICT and ICC) are
familiar. It has been suggested that these disorders
result from Wilson’s disease gene, well established as
causing mild copper accumulation, but causing no
medical problems with the usual intake of copper. The
concept is that when the main source of nutrition and/
or water for infants has a high content of copper,
Wilson’s disease can become a dominant, and man-
ifests in heterozygote’s (Butler et al. 2001). An
alternate hypothesis is that there is a gene, not
discovered yet, which impairs copper excretion caus-
ing these syndromes (Brewer 2003a, b).
Aceruloplasminemia
Aceruloplasminemia—an autosomal recessive dis-
ease—is caused by mutations in the Cp allele on
chromosome 3q, and results in a total absence of Cp in
the blood. Therefore an iron accumulation, causing
clinical problems in the brain and liver is observed
(Brewer 2003a, b). The absence of Cp does not
produce marked changes in copper metabolism but
only alters iron metabolism. It produces a gradual
accumulation of iron in the liver, pancreas, retina and
central nervous system. Cp possesses ferroxidase
activity for mobilization and utilization of the stored
iron from Fe(II) to Fe(III) (Tapiero et al. 2003; Harris
et al. 1998), but it isn’t the only way of in which iron
ions, could be oxidized. They can be oxidized for
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transferrin loading also by hephaestin, cytochromes
and in Fenton—like- reactions (Chen et al. 2014).
Alzheimer disease
Alzheimer disease (AD) is a multifactorial disorder in
which many altered cellular processes are involved,
such as oxidative stress, neuroinflammation, impair-
ments in energy metabolism, and others. Major
histopathological features associated with AD are
senile plaques and neurofibrillary tangles, related to
aberrant processing of amyloid precursor protein
(APP) leading to the deposition of amyloid b and
hyperphosphorylation of tau protein, respectively
(Gonzalez-Dominguezet al. 2014, Arnal et al. 2013;
Atwood et al. 2000). The main brain regions affected
in AD include the entorhinal cortex, hippocampus,
basal forebrain and amygdale, which exhibit synaptic
loss resulting in extensive brain atrophy. Clinically,
AD patients present with symptoms of memory loss,
altered personality and behavior, and impaired exec-
utive function. The estimated copper content in a
healthy human adult brain is 7–10 % of total body
copper, similar to that found in the liver, the major
organ of copper homeostasis. In a human adult brain,
copper is particularly enriched in the hippocampus and
substantia nigra (Hung et al. 2013).
Recent findings report that alteration of homeostasis
of biological metallic ions including zinc, iron, alumi-
num and copper, plays an important role in the
pathogenesis of AD. Special attention has been paid
on homeostasis of copper (Duce et al. 2010; Uriu-
Adams and Keen 2005; White et al. 1999; Ugarte et al.
2013). Copper is an important transition metal in
various metabolic pathways and prevents excessive
activity of N-methyl-d-aspartate receptors, which are
excitatory neurotransmitter receptors (Noda et al.
2013; Eskici and Axelsen 2012). Copper levels in
plasma and free serum copper levels are known to
elevate with aging and to be elevated in AD brains
(Noda et al. 2013; Eskici and Axelsen 2012). Some
authors demonstrated that free copper (also known as
NCBC or non-ceruloplasmin-bound Cu) is elevated in
the blood of AD patients, negatively correlates with
cognition, and predicts the rate of loss of cognition
(Arnal et al. 2013). Other studies suggest that copper
can promote amyloid b aggregation. In addition,
unusually high concentration of copper (400 lM) has
been observed in Alzheimer’s senile plaques. A
number of reports have hypothesized that homodimer-
ization of APP can affect amyloid b production.
Interestingly, some copper binding domains have been
identified on APP, next to the growth factor-like
domain within the N-terminal domain that consists of
four amino acids, His-147, His-151, Try-168 and Met-
170 (Noda et al. 2013; Eskici and Axelsen 2012;
Atwood et al. 2000).
Metal-induced oxidative stress is another mechanism
that can lead to profound neurodegenerative processes
in AD. As copper is a redox active metal, aberrations in
its’ homeostasis may create favorable conditions for
superoxide-yielding redox cycling and oxidative dam-
age to susceptible regions in brain, where easily
oxidized substrates abound (e.g. membrane polyunsat-
urated lipids), and redox-based neurochemical reactions
occur (Gromadzka et al. 2014, Lopes da Silvaet al.
2013). Paradoxically, the utilization of copper’s redox
activity in Fenton or Haber–Weiss reactions promotes
the production of toxic reactive oxygen species (ROS).
Therefore, the dichotomous nature of copper demands a
precise regulation to maintain an appropriate level and
distribution in the brain, and to prevent inadvertent
interactions with other cellular components (Hung et al.
2013; Duce et al. 2010).
Prion diseases
The cellular prion protein, PrPC, a copper binding
protein located predominantly at the synapse, is GPI-
anchored cell surface glycoprotein, found in the brain,
spinal cord and peripheral tissues. It has a causative role
in the pathogenesis of Creutzfeldt–Jacob disease, Gerst-
mann–Straussler–Scheinker disease and fatal familial
insomnia, known as prion diseases (Mittergger et al.
2009; Hornshaw et al. 1995a, b). PrPC is reported to have
copper-dependent SOD-like activity. It is a 33-35 kDa
protein with four or five ions of Cu bound to four
identical sequences of eight amino acids in the N-ter-
minal region of the protein. Copper lends structural
stability to the N-terminal region and also to other parts
of the molecule (Tapiero et al. 2003; Hornshaw et al.
1995a, b). Transition of PrPC from a predominantly a-
helical form to a b-sheet rich isoform seems to be the
cause of transmissibility and pathogenesis (Brown 2003;
Kramer et al. 2001). In the late 90’s, it was shown that
copper stimulates endocytosis of the prion protein.
Copper stimulation of PrPC endocytosis requires the
highly conserved Cu(II) binding repeats in the protein
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(Mittergger et al. 2009; Hijazi et al. 2003; Pauly and
Harris 1998). It was also shown that copper ions
facilitate the renaturation of guanidine-denatured PrPC
molecules to form the protease-resistant infectious prion
particle that accumulates in the endosome due to
defective recycling of this particle to the plasma
membrane. It has been reported that the enhanced
expression of PrPC increases cell stability to take up
copper (Pauly and Harris 1998; Ironside 1996). It also
appears to increase its resistance to copper toxicity and
oxidative stress. Exposure on to large non-physiological
concentrations of Cu(II) ions induces endocytosis of this
protein and brings its copper into the cell. It seems that
the role of Cu(II) ions in the pathogenesis of prion
disease is rather complex (Tapiero et al. 2003; Bochar-
ova et al. 2005). Copper may change the structure and
convert capability of PrPC with further implications to
cell signaling (Brown 2003; Hijazi et al. 2003). But on
the other hand a higher availability of copper may induce
some kind of oxidative stress conditions that generate an
increased level of PrPC (Kramer et al. 2001).
Diabetes
Diabetes mellitus is often found in aceruloplasminemic
individuals. It is currently thought that the diabetes is an
adverse consequence of increased Fe ions accumulation
in the pancreas due to the lack of ferroxidase activity in
the tissue (Uriu-Adams and Keen 2005). While altered
copper metabolism can directly or indirectly alter
glucose homeostasis, conversely, diabetes can perturb
copper metabolism (Takahashi et al. 1996). In rodents,
diabetes results in increased copper concentration in the
liver and kidney, which is associated with an increased
metallothionein level. The presence of copper ions in
blood can increase the rate of advanced glycosylated
end products formation, which is associated with the
pathogenesis of secondary complications in diabetes.
Others studies have shown that plasma concentrations
seemed to be higher in diabetic humans, compared to
non-diabetic—plasma copper was particularly high in
diabetics with complications, such as retinopathy,
hypertension and microvascular disease (Uriu-Adams
and Keen 2005).
Angiogenesis and cancer
The role of copper in the growth and progression of
malignancy has been the subject of intense
investigations, since copper ions generate free radi-
cals, which may activate signaling pathways for cell
proliferation. The evidence obtained over the years has
shown that cancer cells generally require more copper
for their growth and metabolism than normal resting
cells. Therefore agents that affect copper homeostasis
are of interest for cancer therapy (Easmon 2002). High
serum and tissue levels of copper were found in
various human tumors including: Hodgkin’s lym-
phoma, leukemia, sarcoma, brain, cervix, lung, breast
and liver cancers. It has also been shown that serum
copper levels return to normal on remission of the
disease or upon removal of the tumor. It has been
demonstrated that copper is required for angiogenic
process (Nasulewicz et al. 2004; Brewer et al. 2000;
Turecky et al. 1984). Many angiogenic promoters also
appear to be dependent on normal level of copper.
Angiogenesis is a complex process that is essential for
the tumor growth, invasion and metastasis. In vitro
studies have shown that copper acts as a critical
angiogenic effector by stimulating the proliferation
and migration of endothelial cells. Recent studies
provide evidence that limiting the biological avail-
ability of copper by penicillamine or TM administra-
tion slows tumor growth (Tapiero et al. 2003).
Lowering copper level moderately with a drug such
as TM produces strong antiangiogenesis and potent
anticancer effects in several rodent models (COX et al.
2001). There may be multiple mechanisms accounting
for the effect of copper-lowering therapy by TM to
inhibit tumor angiogenesis. But it is most probable that
TM suppresses NF-jB protein levels and transcrip-
tion, and NF-jB is known as regulator of many genes
involved in tumor invasion, angiogenesis and metas-
tasis (Pan et al. 2002). Recent studies have shown that
copper directly stimulates angiogenesis. Others stud-
ies have shown that copper seems to be necessary for
endothelial cell activation, as it stimulates their
proliferation and migration (Nasulewicz et al. 2004).
Several angiogenic factors, such as VEGF, basic
fibroblast growth factor, tumor necrosis factor alpha
and interleukin 1 have been found to be copper
activated (Brewer et al. 2000). Activation factors bind
to endothelial cells, switch them from G0 into G1
phase and force proliferation (Brewer 2003a, b;
YoshiiI et al. 2001). Copper also binds to several
proteins (heparin, ceruloplasmin), which therefore
gain angiogenic activity manifested by stimulation of
endothelial cells (Turecky et al. 1984). Mild copper
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deficiency in animals strongly inhibits the response to
various normally angiogenic stimuli when placed in
the cornea. It has been showed that tumors implanted
in the brains of copper-deficient animals had reduced
growth and invasive properties (Pan et al. 2002; COX
et al. 2001).
Immune response
Most recently it has been discovered that fibrotic and
inflammatory cytokines are also copper dependent.
Copper metabolism is altered in inflammation pro-
cess—its level in serum rises. Copper itself is impor-
tant for immune response, including the production of
IL-2 by activated lymphocytic cells and it supports the
activity and effectiveness of cellular and humoral
immunity by influence on T lymphocytes (Tapiero et.
al 2003; Percival 1998).
Cardiovascular disease
It has been demonstrated that experimental copper
deficiency significantly increases susceptibility of
lipoproteins and cardiovascular tissues to lipid perox-
idation, thus increasing the risk of cardiovascular
disease (Percival 1998). The heart and heart vessels
are particularly vulnerable to copper deficiency.
Alterations in cardiac morphology include enlarged
myocytes, derangement of myofibrils, fragmented
basal laminae at capillary-myocyte interfaces, and
mitochondrial proliferation, swelling and fragmenta-
tion (Uriu-Adams and Keen 2005). Also electrocar-
diographic abnormalities and impaired contractile and
mitochondrial respiratory functions are observed in
copper deficient hearts. Hypertrophic cardiomyopathy
is noted in humans with mutations in copper chaper-
one for cytochrome c oxidase. Copper deficiency leads
also to anemia, since cytochrome oxidase is required
for blood formation. Copper depletion experiments
also show abnormalities in blood pressure and aortic
stenosis (Uriu-Adams and Keen 2005; Rowland and
Schneider 2001). Repletion of Cu by dietary copper
supplementation reverses many of the adverse histo-
pathological and hemodynamic effects on the heart,
possibly through the normalization of the expression
of genes, which are involved in contractility, calcium
cycling, inflammation and extracellular matrix metab-
olism (Uriu-Adams and Keen 2005). There are also
data showing a correlation between copper deficiency
and atherosclerosis. An increased concentrations of
total cholesterol and LDL with reduction of HDL are
observed in the subjects fed an experimental diet low
in copper (Brewer 2003a, b, Rowland and Schneider
2001).
Oxidative stress related disorders
The occurrence of copper on two oxidize states allows it
to serve as cofactor in redox reactions such as
cytochrome c oxidase (involved in the mitochondrial
electron transport chain) and superoxide dismutase
(involved in the detoxification of reactive oxygen
species). An excess of copper could result in oxidative
stress related health disorders, many of which can be
linked partially to its redox reactivity. Copper has been
suggested to facilitate oxidative tissue injury through a
free radical mediated pathway analogous to the Fenton
reaction. Copper deficiency also affects directly or
indirectly the components of the oxidant defense system
and as a result increased ROS and oxidative damage to
lipid, DNA and proteins have been observed in human
cell culture models. Copper on Cu(I) state can bind
directly to free thiols of cysteine or methionine, resulting
in oxidation and subsequent cross-links between pro-
teins leading to impaired activity. Copper on Cu(II) state
prefers nitrogen donors, such as histidine, or oxygen
donors, such as glutamate or aspartate.
Temporary deficiency and toxicity of copper
Copper deficiency has been described mostly in
infants on total parenteral nutrition without adequate
mineral supplementation or in persons with persistent
nephritic syndrome that increases copper losses. Low
copper status has been associated with bone malfor-
mation during development, increased osteoporosis,
impaired melanin synthesis, poor immune response,
therefore increasing frequency of infections, cardio-
vascular disease, alterations with cholesterol metabo-
lism, and disturbance of metabolism of other trace
elements, such as iron mobilization.
Copper toxicity is usually an acute episode result-
ing from copper contamination of drinking water or
food (Puig and Thiele 2002). The symptoms are
nausea, vomiting and diarrhea, abdominal pain, head-
ache, tachycardia, respiratory difficulties, hemolytic
anemia. They begin in the most sensitive subjects at
616 Biometals (2014) 27:611–621
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the concentration of 3 mg/l (Pen˜a et al. 2000). Some
investigators have suggested that chronic consumption
of drinking water with elevated Cu concentration may
be risky for susceptible populations, including infants,
young children and individuals who are heterozygotic
for Wilson’s disease (Uriu-Adams and Keen 2005;
Ugarte et al. 2013).
Cu-requiring/depending proteins
Copper is an important micronutrient that forms part of
several proteins involved in a variety of biological
processes indispensable to sustain life. Cu-requiring
proteins are involved in a variety of biological processes
and deficiency in these enzymes or alterations in their
activities often cause disease states or pathophysiolog-
ical conditions (Puig and Thiele 2002). Some authors
consider these proteins as better indicators of metabol-
ically active copper stores than the serum concentrations
of copper, or Cp because the enzyme activities are
sensitive to changes in copper stores.
Ceruloplasmin (Cp)
Cp is a single polypeptide chain at about 132 kDa. The
Cp protein contains seven copper ions, accounting for
more than 70 % of the total copper circulating in the
serum and it provides a major link between copper and
iron metabolism (Harris et al. 1998). Besides its
potential role in copper delivery to cells and excretion
of copper from body, this glycoprotein presents
ferroxidase activity and catalyzes the conversation of
ferrous to ferric iron which is then transferred to
transferrin. This change is helpful to provide iron, in
the form needed to bind to transferrin (iron Fe(III)
plasma carrier), as it emerges from cells for further
transport from the bone marrow to red blood cells,
where most iron resides (Harris et al. 1998). In severe
copper deficiency, there is little or no copper contain-
ing Cp in plasma and tissues, and therefore, iron
accumulation in the liver occurs (Tapiero et al. 2003;
Turecky et al. 1984; Takahashi et al. 1996). Immuno-
reactive or enzymatically measured Cp levels are used
to evaluate the body storage of copper, because Cp
acts as an acute-phase reactive protein to stress and
trauma conditions—its concentration is elevated in
response to inflammation, infection and various
chronic diseases such as arthritis.
Cytochrome-c oxidase
Cytochrome c oxidase (CCO) is bound with inner
mitochondrial membrane. It is a component of the
mitochondrial respiratory chain so it takes part in
energy production. It has four redox active metal sites,
two hem sites and two copper sites. It is the terminal
oxidase in most aerobic organisms and reduces
molecular oxygen (O2) to water. In addition to O2
reduction, cytochrome C oxidase pumps protons from
the inside to the outside of the membrane (Tapiero
et al. 2003). Studies have shown that the activities of
CCO were reduced in response to copper depletion.
Metallothioneins (MTs)
Metallothioneins (MTs) are cysteine-rich metal bind-
ing proteins at low molecular weight. They come at
least in two isoforms encoded by several genes. The
biological roles of metallothioneins are: detoxification
of metals ions, including non-essential and excess of
essential metals ions, storage of essential microele-
ments, sequestration of ROS and nitrogen species
(Ogra et al. 2006). MTs bind Zn, Cu and Cd ions,
mainly, however, copper is bound most tightly and can
displace others ions. Under reducing conditions,
metallothioneins can bind copper ions and render
them redox inactive. Metallothioneins are induced
under Cu-deficient conditions to maintain the activi-
ties of intracellular Cu-proenzymes such as cyto-
chrome C oxygenase, and to scavenge ROS instead of
copper containing antioxidants, such as Cu/Zn—SOD
(Ogra et al. 2006).
Cu/Zn superoxide dismutase
Cu/Zn—SOD converts superoxide anions to peroxide
for further disposal (by catalase and glutathione
peroxidase) and is found largely in cytosol. Mutations
of Cu/Zn-SOD have been recently of interest in
connection with amyotrophic lateral sclerosis, where a
gain of function is responsible for the underlying
neurological symptomatology (Roney and Colman
2004; Tapiero et al. 2003). The loss of kinetic stability
is responsible for the exposition of the sulfide bond to
reduction and hydrophobic surface area to potential
interaction with other proteins (Itoh et al. 2009).
Thereby, it has been suggested that the mutant protein
binds copper abnormally, generating ROS. Copper is
Biometals (2014) 27:611–621 617
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more important than zinc for kinetically stabilizing
SOD. The absence of Cu from SOD may result in a
protein prone to aggregation, possessing enhanced
oxidative activity and abnormally interacting with
other proteins (Lynch and Colo´n 2005)
Enzymes activated by copper ions
Catalase
Catalase is a Fe-binding enzyme that catalyzes the
conversion of hydrogen peroxide to water and oxygen.
Expression of cardiac-specific catalase prevents injury
to the heart following oxidative insults. Copper
deficiency can lead to a reduction in catalase activity
in tissues, such as heart and liver (Uriu-Adams and
Keen 2005).
Glutathione peroxidase (GPx)
Glutathione peroxidase converts hydroperoxide com-
pounds to hydroxide compounds. The activity of this
enzyme has been reported to be decreased in case of
copper deficiency in the liver and plasma. Cu
deficiency may reduce GPx activity by decreasing
enzyme’s mRNA (Uriu-Adams and Keen 2005).
Hephaestin
Hephaestin is a homolog of Cp and it shares some of its
characteristics. It is transmembrane protein of about
134 kDa, located in trans-Golgi vesicles. It has
ferroxidase activity and it is involved in intestinal
iron absorption (intestinal iron efflux). It may oxidize
iron ions for binding to apotransferrin, allowing its
release into the blood as holotransferrin (Tapiero et al.
2003). A consequent of hephaestin deficiency is sex-
linked anemia.
Cartilage matrix glycoprotein
Cartilage matrix glycoprotein—is another intracellu-
lar homolog of Cp with ferroxidase and oxidase
activities. It is located in the vesicular portions of
chondrocytes, as well as in the epithelial cells of the
eye. It may play a role in the formation of the
extracellular matrix (Tapiero et al. 2003).
Protein-6-lysine oxidase
Lysyl oxidase plays crucial role in the formation,
maturation and stabilization of connective tissues. A
lack of this enzyme is manifested by a laxity in
collagen and skin and reflects a defect in collagen and
elastin crosslinking. Lysyl oxidase is part of the
extracellular matrix of organs and tissues in the body,
including cartilage and bone. It is a multimer protein
composed of 32 kDa subunits, which requires copper
for its activity (Tapiero et al. 2003).
Other important Cu-dependent enzymes are: tyros-
inase (necessary for melanin production), dopamine-
b-hyroxylase (important in catecholamine produc-
tion), peptidylglycine a-amidating monooxygenase
(required for neuropeptide and peptide hormone
processing), monoamine oxidase (needed for pigment
and neurotransmiter production and metabolism)
(Uriu-Adams and Keen 2005).
Complexes of copper
Current interest in copper complexes comes from their
potential use as antimicrobial, antiviral, anti-inflamma-
tory, antitumor agents, enzyme inhibitors or chemical
nucleases. Biochemical action of copper’s complexes
with non-steroidal anti-inflammatory drugs (NSAIDs) has
been recently studied. Numerous Cu(II) complexes of
NSAIDs, showing enhanced anti-inflammatory and anti-
ulcerogenic activity as well as reduced gastrointestinal
toxicity compared to the un-complexed drug have been
prepared and structurally characterized (Joseph and
Nagashri 2012). It is likely that copper complexes interact
with enzymes and inhibit vital cell functions, rather than
interact with DNA and induce crosslinking (Iakovidis
et al. 2011). Cu(II) chelates of salicylaldoxime and
resoecylaldoxime are potent antiproliferative agents,
exhibiting strong cytotoxic effects, comparable to that of
adriamycin, by inducing cell arrest and apoptosis (Ferreza
et al. 2010). Their action may involve the inhibition of the
enzyme topoisomerase II activity by preventing dimer
formation of enzyme and its reaction with DNA. The
complex 2,6-bis(benzimidazo-2-yl)pyridine copper(II)
chloride has been show to exhibit metalloprotease
activity. Complexes of carboxyamidrazones exhibit
enhanced antiproliferative activity against B16F10 mouse
melanoma cells (Fernandes et al.2012). It is suggested that
the combination of copper with carboxyamidrazone
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ligands may facilitate intracellular transportation and
block estrogen receptors. Copper complexes that exhibit
high SOD-like activity are potent drugs for prion disease
since such activity is correlated with antiprion activity. It is
known that prion proteins can bind Cu(II) ions with high
specificity as they possess a number of copper sites.
Moreover in the development of prion disease, copper
may modulate the rate of protein misfolding.
Tetradentate Schiff base ligands derived from Knoe-
venagel condensation of b-ketoanilides and furfural with
O-phenylenediamine and diethylmalonate, and their
Cu(II) complexes showed antibacterial activity against
Eschericia coli, Salmonella typhi, Staphylococcus aur-
eus, Kliebsiella pneumoniae and Pseudomonas aerugin-
osa. Tetradentate Schiff base and their Cu(II) complexes
showed antifungial activity against Aspergillus niger,
Rhizopus stolonifer, Aspergillus flavus, Rhizoctonia
bataticola and Candida albicans. Antifungal activity of
clomiphene citrate copper compounds has been deter-
mined against two fungi: Aspergillus flavus and Asper-
gillus niger (Creaven et al.2010). Copper(II) complexes
containing Schiff bases derived from S-benzylidene
thiocarbamates and saccharinate showed anticancer
properties (Katwal et al. 2013). These complexes have
been active against the leukemic cell line HL-60 and the
activities being higher than the Doxorubicin. Isatin-
Schiff base copper(II) complexes possessed pro-apopto-
tic activity. Copper complex with mixed ligands such as:
phenanthroline or 2,20-bipyridine and acetylacetonate or
glycinate are known as cassiopeinas. They exhibit
significant antineoplastic activity in vitro and in vivo,
against variety of tumor cell lines (Ferreza et al. 2010).
Semicarbazone Cu(II) complexes imitate superoxide
dismutase activity. Copper(II) complexes with phenolic
hydrazone have been used as dyes, bakelite and drugs.
Amido-Schiff base form chelates with Cu(II) and act as a
thrombin inhibitors. Copper complex with isatin and its
derivatives have shown a variety of biological effects,
including inhibition of monoamine oxidase. Pyrrolidine
dithiocarbamate complexes of Cu(II) were reported to
cause the inhibition of the proteasome in vitro against
LNCaP prostate cancer cells. These copper complexes
resulted in low levels of proteasomal chymotrypsin-like
activity and the accumulation of ubiquitinated proteins.
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